NEKTAR THERAPEUTICS (NKTR) FY2026 Q2 P&L / Income Statement

NEKTAR THERAPEUTICS (NKTR) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. Consolidated revenue, costs and expenses.

Total revenue

10,131,000 US dollars

Total operating costs and expenses

52,472,000 US dollars

Loss from operations

negative 42,341,000 US dollars

Total non-operating income (expense), net

2,040,000 US dollars

Loss before provision (benefit) for income taxes and equity method investment

negative 40,301,000 US dollars

Provision (benefit) for income taxes

2,000 US dollars

Net loss

negative 40,622,000 US dollars

Undisclosed sources

10,131,000 US dollars. The filing reports revenue as one line and discloses no sources of it.

Research and development (including $1,137 and $613 for the three months ended June 30, 2026 and 2025, respectively, from a related party; and $2,845 and $821 for the six months ended June 30, 2026 and 2025, respectively, from a related party)

39,129,000 US dollars

General and administrative

12,765,000 US dollars

Restructuring and impairment

578,000 US dollars

Loss from equity method investment

negative 319,000 US dollars. Reported below-tax contribution to net income.

Chart connections

• Revenue minus operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.